Ambrilia Biopharma Inc.
TSX : AMB

Ambrilia Biopharma Inc.

June 13, 2006 08:00 ET

Media Advisory: Annual General Meeting of Shareholders of Ambrilia Biopharma and Webcast

MONTREAL, QUEBEC--(CCNMatthews - June 13, 2006) - Mr. Hans J. Mader, President and Chief Executive Officer of Ambrilia Biopharma Inc. (TSX:AMB) invites the news media to the Annual General Meeting of Shareholders that will be held on Tuesday, June 20, 2006, at 10:30 a.m. E.T., in the Salon International I-II of the Centre Mont-Royal, 2200 Mansfield Street in Montreal.

Dr. Max Link, Chairman of the Board, will be presenting the formal portion of the meeting followed by Mr. Hans J. Mader, President and Chief Executive Officer, who will be joined by Dr. Bonabes de Rouge, Executive Vice-President and Chief Scientific Officer, and Mrs. Monique Letourneau, Executive Vice-President, Finance and Chief Financial Officer, to present this year's events, mainly the formation of Ambrilia, the most recent developments and future outlook.

A brief media session will be held after the meeting at approximately 11:45 a.m. E.T., in the Room Mansfield 10.



DATE BOOK:

EVENT: Ambrilia - Annual General Meeting of Shareholders

DATE: Tuesday, June 20, 2006

VENUE: Centre Mont-Royal, Salon International I-II
2200 Mansfield Street, Montreal

TIME: Annual General Meeting: 10:30 a.m.
Session with Media: 11:45 a.m.
Light Lunch: 12:15 p.m.


Ambrilia will host a live webcast of the event. Interested parties may access the webcast and presentation at www.ambrilia.com on the Conference calls and Webcasts page of the Investor section.

ABOUT AMBRILIA BIOPHARMA

Ambrilia Biopharma Inc. (TSX:AMB) is a biopharmaceutical company developing innovative therapeutics in the fields of oncology and infectious diseases. Ambrilia's product portfolio includes proprietary mid to early-stage products; an anti-cancer therapeutic peptide (PCK3145), a novel anti-cancer therapy (TVT-Dox), two oncology specialty generics (Octreotide, Goserelin), the first of which is late-stage and value-added, and promising anti-HIV treatments (PPL-100, SPC3). Ambrilia's head office, research and development and manufacturing facilities are located in Montreal with a regional office in France. For more information, please visit the Company's web site: www.ambrilia.com

Forward-looking statements

This press release contains forward-looking statements that reflect the Company's current expectation regarding future events. The forward-looking statements involve risks and uncertainties. Actual events could differ materially from those projected herein and depend on a number of factors including, but not limited to, changing market conditions, successful and timely completion of clinical studies, uncertainties related to the regulatory approval process, establishment of corporate alliances and other risks detailed from time to time in the Company's filings. Such statements are also based on various assumptions, including the successful and timely completion of clinical studies on Ambrilia's products demonstrating efficacy and safety for human use, their successful commercialization within the forecasted timelines and the attainment of the forecasted milestone payments and other revenues. While Ambrilia anticipates that subsequent events and developments may cause Ambrilia's views to change, Ambrilia specifically disclaims any obligation to update these forward-looking statements.

www.ambrilia.com

Contact Information